While most amino acid PET studies focused mainly on IDH-wildtype glioma patients, the available literature regarding its use in patients with IDH-mutant gliomas suggests that this technique also adds valuable clinical information for decision-making. This evidence concerns the gene IDH2 and central nervous system cancer.